Aytu Biopharma (AYTU) investor relations material

Strategic realignment and financial performance

• Refocused on core prescription business, exiting unprofitable segments and in-house manufacturing by end of 2024.

• Divested consumer health business by mid-2025, improving profitability and margins.

• Achieved consistent positive adjusted EBITDA of $9–10 million over the past three years.

• Maintains a solid revenue base with over $66 million in trailing 12-month net revenues.

• Ended June 2025 with over $30 million in cash and manageable debt refinanced to 2029.

Product portfolio and upcoming launch

• Core focus on CNS brands, especially ADHD medications Adzenys XR-ODT and COTEMPLA XR-ODT.

• Preparing to launch Exxua, a novel antidepressant for major depressive disorder, in Q4 2025.

• Exxua is FDA approved, weight neutral, and does not cause sexual dysfunction, differentiating it from SSRIs/SNRIs.

• Exxua targets the 5-HT1A receptor, offering a unique mechanism of action.

• Patent protection for Exxua extends through late 2030, with plans for lifecycle extension.

Commercial infrastructure and market opportunity

• 40-person sales force already established in psychiatry, covering 60% of major depressive disorder prescribers.

• Exxua will become the primary focus, leveraging existing relationships with psychiatrists.

• The depression market exceeds 340 million annual prescriptions and $22 billion in value.

• Exxua will be priced at a premium, with favorable reimbursement expected from Medicaid and Medicare.

• Recent capital raise and stable base business will fund Exxua’s launch and promotional activities.